Carver Biosciences
Company Type: Therapeutic development
Main focus: Developing CRISPR-based therapies for RNA viruses that infect humans
Company stage: Pre-clinical
Diseases: Human RNA viral infections
Genome-editing tool: CRISPR-Cas13
Funding stage: Seed
Location: Boston, Massachusetts, USA
Website: Carver Biosciences - Home
Pipeline:
Partners:
Carver Biosciences is a biotechnology company focused on developing broad-spectrum anti-virals using CRISPR technology. Carver’s approach is a programmable, platform technology that could provide treatment options for various human-infecting RNA viruses. The company’s technology is based on the programmable function of CRISPR’s guide RNA sequence. Currently, Carver is investigating the use of CRISPR-Cas13 to target and destroy respiratory viruses at the RNA level.